Information Provided By: 
Fly News Breaks for March 18, 2015
NKTR
Mar 18, 2015 | 08:07 EDT
Brean Capital said it would use any weakness following Nektar's announcement of top line results for its breast cancer drug trial as a buying opportunity. The firm noted the trial missed its primary and secondary endpoints and has removed the revenue from their estimates, leading to a lowering of its price target to $17 from $20, but maintained its Buy rating on Nektar shares, citing its other opportunities.
News For NKTR From the Last 2 Days
There are no results for your query NKTR
